Evidence map›Paper›PMID 39210566›Full record

ArticleThe American journal of surgical pathology2024

Botryoid-type Embryonal Rhabdomyosarcoma: A Comprehensive Clinicopathologic and Molecular Appraisal With Cross-comparison to its Conventional-type Counterpart.

Aarti E Sharma, Josephine K Dermawan, Sarah Chiang, Leonard H Wexler, Cristina R Antonescu

Abstract readComparative Study
In one paragraph

Article in The American journal of surgical pathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Aarti E SharmaDepartment of Pathology & Laboratory Medicine, Memorial Sloan Kettering Cancer Center.
Josephine K DermawanDepartment of Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH.
Sarah ChiangDepartment of Pathology & Laboratory Medicine, Memorial Sloan Kettering Cancer Center.
Leonard H WexlerDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY.
Cristina R AntonescuDepartment of Pathology & Laboratory Medicine, Memorial Sloan Kettering Cancer Center.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Targeting Oncogenic Pathways in Genetically Complex SarcomasP50CA217694 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI William D. Tap · 2018 to 2026
$21.5M
NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA217694
6 · The paper itself

Abstract

Embryonal rhabdomyosarcoma (ERMS) is the most common subtype of RMS, occurring in soft tissue and visceral sites of young children, and is associated with favorable outcomes. A subset occurs in mucosal-lined luminal structures, displaying a unique grape-like growth termed as "botryoid-type." To further delineate the differences between conventional (cERMS) and botryoid-type (bERMS) RMS, we performed a comparative histologic review and comprehensive molecular profiling of 48 cases (25 bERMS and 23 cERMS). All tumors were subjected to a hybridization capture-based targeted matched tumor-normal DNA NGS assay. The mean age was 17 and 7 years for bERMS and cERMS, respectively. Most bERMS were female with a predilection for the gynecologic tract (75%), while cERMS had a slight male predominance and were preferentially located in abdominopelvic and paratesticular sites (30%, each). All bERMS exhibited an exophytic, bulbous architecture accompanied by a subepithelial "cambium layer." Distinctive germline alterations were detected, with DICER1 (18%) and FH (6%) mutations only in bERMS, and rare TP53, VHL , and APC mutations in cERMS. Similarly, contrasting somatic genomic landscapes were observed, with frequent DICER1 (52%, P **<0.0001) and TP53 (36%, P *<0.05) alterations exclusively in bERMS. Cartilaginous differentiation was only observed in DICER1 -mutated bERMS. All patients had longitudinal follow-up. bERMS patients with somatic/germline DICER1 mutations showed significantly improved recurrence-free survival compared with that of DICER1 -wild type patients ( P *<0.05). Moreover, bERMS showed improved disease-specific survival compared with that of cERMS, with 8% versus 30% ( P *<0.05) dead of disease, respectively. In summary, we compare the molecular underpinnings of the largest cohort of bERMS and cERMS with targeted DNA sequencing and long-term follow-up data. Our findings reveal divergent genomic topographies between the 2 groups, with bERMS showing unique germline and somatic abnormalities, including enrichment in DICER1 and TP53 alterations, and a trend towards improved survival.

Indexed as

Biomarkers, TumorRhabdomyosarcoma, EmbryonalAdolescentAdultChildChild, PreschoolDEAD-box RNA HelicasesDNA Mutational AnalysisFemaleGenetic Predisposition to DiseaseGerm-Line MutationHumansMalePhenotypeRibonuclease IIIYoung AdultBiomarkers, TumorDEAD-box RNA HelicasesDICER1 protein, humanRibonuclease IIIbotryoidembryonal rhabdomyosarcomagermline

Identifiers

PMID39210566
PMCPMC12117734

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.